ClinicalTrials.gg

TargetBeta

IL23A

interleukin 23 subunit alpha · also SGRF, IL23P19, IL-23, IL-23A · Interleukins

6 programs in company-led studies act on IL23A, from 5 companies: 0 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
guselkumabruleJohnson & Johnsonphase 46019 runningIL12BChEMBL
risankizumabruleAbbViephase 46816 runningIL12BChEMBL
mirikizumabruleEli Lillyphase 4367 runningIL12BChEMBL
SHR-1139Jiangsu HengRui Medicinephase 287 runningIL36Rthe company's pipeline
ABBV-547AbbViephase 222 running–the company's pipeline
GSK4528287GlaxoSmithKlinephase 111 runningIL18the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.